{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:09:48Z","timestamp":1791227388897,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97889-1","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T13:54:42Z","timestamp":1745070882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between statin use and cataract formation in a retrospective cohort study using Japanese health screening and claims data"],"prefix":"10.1038","volume":"15","author":[{"given":"Kazuhiro","family":"Kawabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Takashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minami","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Sahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Ooba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"97889_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-74-1-1","volume":"74","author":"WB Kannel","year":"1971","unstructured":"Kannel, W. B., Castelli, W. P., Gordon, T. & McNamara, P. M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann. Intern. Med. 74, 1\u201312 (1971).","journal-title":"Ann. Intern. Med."},{"key":"97889_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2020.12.013","volume":"319","author":"D Atar","year":"2021","unstructured":"Atar, D. et al. New cardiovascular prevention guidelines: how to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention. Atherosclerosis 319, 51\u201361 (2021).","journal-title":"Atherosclerosis"},{"key":"97889_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.15585\/mmwr.mm6447a1","volume":"64","author":"C Mercado","year":"2015","unstructured":"Mercado, C. et al. Prevalence of cholesterol treatment eligibility and medication use among adults\u2013United States, 2005\u20132012. MMWR Morb Mortal. Wkly. Rep. 64, 1305\u20131311 (2015).","journal-title":"MMWR Morb Mortal. Wkly. Rep."},{"key":"97889_CR4","doi-asserted-by":"publisher","unstructured":"Pinho-Gomes, A. C., Peters, S. A. E., Thomson, B. & Woodward, M. Sex differences in prevalence, treatment and control of cardiovascular risk factors in England. Heart. https:\/\/doi.org\/10.1136\/heartjnl-2020-317446","DOI":"10.1136\/heartjnl-2020-317446"},{"key":"97889_CR5","unstructured":"Ministry of Health. Labour and Welfare, Japan. Prevalence of dyslipidemia in Japan (in Japanese) (2024). https:\/\/www.mhlw.go.jp\/content\/10900000\/000687163.pdf"},{"key":"97889_CR6","unstructured":"e-Stat. Statistics on patients with dyslipidemia in Japan (in Japanese) (2024). https:\/\/www.e-stat.go.jp\/dbview?sid=0004002481"},{"key":"97889_CR7","doi-asserted-by":"publisher","first-page":"846","DOI":"10.5551\/jat.GL2017","volume":"25","author":"M Kinoshita","year":"2018","unstructured":"Kinoshita, M. et al. Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J. Atheroscler Thromb. 25, 846\u2013984 (2018).","journal-title":"J. Atheroscler Thromb."},{"key":"97889_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(14)61009-6","volume":"384","author":"PM Ridker","year":"2014","unstructured":"Ridker, P. M. LDL cholesterol: controversies and future therapeutic directions. Lancet 384, 607\u2013617 (2014).","journal-title":"Lancet"},{"key":"97889_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111\u2013188 (2020).","journal-title":"Eur. Heart J."},{"key":"97889_CR10","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2022.12138","volume":"328","author":"R Chou","year":"2022","unstructured":"Chou, R. et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US preventive services task force. JAMA 328, 754\u2013771 (2022).","journal-title":"JAMA"},{"key":"97889_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1001\/archinternmed.2012.2145","volume":"172","author":"J Gutierrez","year":"2012","unstructured":"Gutierrez, J., Ramirez, G., Rundek, T. & Sacco, R. L. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch. Intern. Med. 172, 909\u2013919 (2012).","journal-title":"Arch. Intern. Med."},{"key":"97889_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","volume":"104","author":"EJ Mills","year":"2011","unstructured":"Mills, E. J. et al. Efficacy and safety of Statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 104, 109\u2013124 (2011).","journal-title":"QJM"},{"key":"97889_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","volume":"8","author":"P Amarenco","year":"2009","unstructured":"Amarenco, P. & Labreuche, J. Lipid management in the prevention of stroke: review and updated meta-analysis of Statins for stroke prevention. Lancet Neurol. 8, 453\u2013463 (2009).","journal-title":"Lancet Neurol."},{"key":"97889_CR14","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"PD Thompson","year":"2003","unstructured":"Thompson, P. D., Clarkson, P. & Karas, R. H. Statin-associated myopathy. JAMA 289, 1681\u20131690 (2003).","journal-title":"JAMA"},{"key":"97889_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.amjcard.2015.11.031","volume":"117","author":"T Acharya","year":"2016","unstructured":"Acharya, T. et al. Statin use and the risk of kidney disease with long-term follow-up (8.4-year study). Am. J. Cardiol. 117, 647\u2013655 (2016).","journal-title":"Am. J. Cardiol."},{"key":"97889_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s13643-021-01863-7","volume":"10","author":"Z Cai","year":"2021","unstructured":"Cai, Z. et al. Surgical resection for patients with recurrent or metastatic Gastrointestinal stromal tumors: a protocol for a systematic review and meta-analysis update. Syst. Rev. 10, 306 (2021).","journal-title":"Syst. Rev."},{"key":"97889_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar, N. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised Statin trials. Lancet 375, 735\u2013742 (2010).","journal-title":"Lancet"},{"key":"97889_CR18","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"JD Steinmetz","year":"2021","unstructured":"Steinmetz, J. D. et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the global burden of disease study. Lancet Glob Health. 9, e144\u2013e160 (2021).","journal-title":"Lancet Glob Health"},{"key":"97889_CR19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0140-6736(17)30544-5","volume":"390","author":"YC Liu","year":"2017","unstructured":"Liu, Y. C., Wilkins, M., Kim, T., Malyugin, B. & Mehta, J. S. Cataracts Lancet 390, 600\u2013612 (2017).","journal-title":"Cataracts Lancet"},{"key":"97889_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/09286580903450346","volume":"17","author":"M Yamada","year":"2010","unstructured":"Yamada, M. et al. Prevalence of visual impairment in the adult Japanese population by cause and severity and future projections. Ophthalmic Epidemiol. 17, 50\u201357 (2010).","journal-title":"Ophthalmic Epidemiol."},{"key":"97889_CR21","doi-asserted-by":"publisher","first-page":"g3743","DOI":"10.1136\/bmj.g3743","volume":"349","author":"CS Desai","year":"2014","unstructured":"Desai, C. S., Martin, S. S. & Blumenthal, R. S. Non-cardiovascular effects associated with Statins. BMJ 349, g3743 (2014).","journal-title":"BMJ"},{"key":"97889_CR22","doi-asserted-by":"publisher","first-page":"e12480","DOI":"10.1111\/1755-5922.12480","volume":"36","author":"C Alves","year":"2018","unstructured":"Alves, C., Mendes, D. & Batel Marques, F. Statins and risk of cataracts: A systematic review and meta-analysis of observational studies. Cardiovasc. Ther. 36, e12480 (2018).","journal-title":"Cardiovasc. Ther."},{"key":"97889_CR23","doi-asserted-by":"publisher","first-page":"e004180","DOI":"10.1161\/JAHA.116.004180","volume":"6","author":"S Yu","year":"2017","unstructured":"Yu, S. et al. Statin use and the risk of cataracts: a systematic review and meta-analysis. J. Am. Heart Assoc. 6, e004180 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"97889_CR24","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1001\/jamaophthalmol.2013.4575","volume":"131","author":"J Leuschen","year":"2013","unstructured":"Leuschen, J. et al. Association of Statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 131, 1427\u20131434 (2013).","journal-title":"JAMA Ophthalmol."},{"key":"97889_CR25","doi-asserted-by":"publisher","first-page":"c2197","DOI":"10.1136\/bmj.c2197","volume":"340","author":"J Hippisley-Cox","year":"2010","unstructured":"Hippisley-Cox, J. & Coupland, C. Unintended effects of Statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340, c2197 (2010).","journal-title":"BMJ"},{"key":"97889_CR26","doi-asserted-by":"publisher","first-page":"104970","DOI":"10.1016\/j.yrtph.2021.104970","volume":"124","author":"HL Chen","year":"2021","unstructured":"Chen, H. L. et al. Effect of hydrophilic and lipophilic Statins on early onset cataract: A nationwide case-control study. Regul. Toxicol. Pharmacol. 124, 104970 (2021).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"97889_CR27","doi-asserted-by":"publisher","first-page":"e0196713","DOI":"10.1371\/journal.pone.0196713","volume":"13","author":"TK Lin","year":"2018","unstructured":"Lin, T. K., Chou, P., Lin, C. H., Hung, Y. J. & Jong, G. P. Long-term effect of Statins on the risk of new-onset osteoporosis: A nationwide population-based cohort study. PLoS One. 13, e0196713 (2018).","journal-title":"PLoS One"},{"key":"97889_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle, A., Laufs, U. & Liao, J. K. Pleiotropic effects of Statins on the cardiovascular system. Circ. Res. 120, 229\u2013243 (2017).","journal-title":"Circ. Res."},{"key":"97889_CR29","first-page":"377","volume":"34","author":"ACJ de Vries","year":"1993","unstructured":"de Vries, A. C. J., Vermeer, M. A., Bloemendal, H. & Cohen, L. H. Pravastatin and Simvastatin differently inhibit cholesterol biosynthesis in human lens. Invest. Ophthalmol. Vis. Sci. 34, 377\u2013384 (1993).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"97889_CR30","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2215\/CJN.0000000000000124","volume":"18","author":"S Bae","year":"2023","unstructured":"Bae, S. et al. Incidence of statin-associated adverse events in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 18, 626\u2013633 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"97889_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0039-6257(96)82007-8","volume":"40","author":"RJ Cenedella","year":"1996","unstructured":"Cenedella, R. J. Cholesterol and cataracts. Surv. Ophthalmol. 40, 320\u2013337 (1996).","journal-title":"Surv. Ophthalmol."},{"key":"97889_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3109\/09286586.2015.1077258","volume":"23","author":"JC Erie","year":"2016","unstructured":"Erie, J. C., Pueringer, M. R., Brue, S. M., Chamberlain, A. M. & Hodge, D. O. Statin use and incident cataract surgery: a case-control study. Ophthalmic Epidemiol. 23, 40\u201345 (2016).","journal-title":"Ophthalmic Epidemiol."},{"key":"97889_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5551\/jat.9.1","volume":"9","author":"Y Hata","year":"2002","unstructured":"Hata, Y. et al. Report of the Japan atherosclerosis society (JAS) guideline for diagnosis and treatment of hyperlipidemia in Japanese adults. J. Atheroscler Thromb. 9, 1\u201327 (2002).","journal-title":"J. Atheroscler Thromb."},{"key":"97889_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5551\/jat.E537","volume":"14","author":"T Teramoto","year":"2007","unstructured":"Teramoto, T. et al. Diagnostic criteria for dyslipidemia. Executive summary of Japan atherosclerosis society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J. Atheroscler Thromb. 14, 155\u2013158 (2007).","journal-title":"J. Atheroscler Thromb."},{"key":"97889_CR35","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.amjcard.2015.09.026","volume":"116","author":"CN Bang","year":"2015","unstructured":"Bang, C. N. et al. Effect of randomized lipid Lowering with Simvastatin and Ezetimibe on cataract development (from the Simvastatin and Ezetimibe in aortic stenosis Study). Am. J. Cardiol. 116, 1840\u20131844 (2015).","journal-title":"Am. J. Cardiol."},{"key":"97889_CR36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","volume":"69","author":"JG Robinson","year":"2017","unstructured":"Robinson, J. G. et al. Safety of very low low-density lipoprotein cholesterol levels with Alirocumab: pooled data from randomized trials. J. Am. Coll. Cardiol. 69, 471\u2013482 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"97889_CR37","doi-asserted-by":"publisher","first-page":"20142","DOI":"10.1038\/s41598-022-24465-2","volume":"12","author":"K Fukai","year":"2022","unstructured":"Fukai, K. et al. Alcohol use patterns and risk of incident cataract surgery: a large scale case-control study in Japan. Sci. Rep. 12, 20142 (2022).","journal-title":"Sci. Rep."},{"key":"97889_CR38","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1136\/bjo.2006.097295","volume":"90","author":"P Raju","year":"2006","unstructured":"Raju, P. et al. Influence of tobacco use on cataract development. Br. J. Ophthalmol. 90, 1374\u20131377 (2006).","journal-title":"Br. J. Ophthalmol."},{"key":"97889_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1471-2415-14-94","volume":"14","author":"L Li","year":"2014","unstructured":"Li, L., Wan, X. H. & Zhao, G. H. Meta-analysis of the risk of cataract in type 2 diabetes. BMC Ophthalmol. 14, 94 (2014).","journal-title":"BMC Ophthalmol."},{"key":"97889_CR40","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1001\/archinte.161.16.2021","volume":"161","author":"RG Schlienger","year":"2001","unstructured":"Schlienger, R. G., Haefeli, W. E., Jick, H. & Meier, C. R. Risk of cataract in patients treated with Statins. Arch. Intern. Med. 161, 2021\u20132026 (2001).","journal-title":"Arch. Intern. Med."},{"key":"97889_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ajo.2011.08.001","volume":"153","author":"DS Fong","year":"2012","unstructured":"Fong, D. S. & Poon, K. Y. Recent Statin use and cataract surgery. Am. J. Ophthalmol. 153, 222\u2013228e1 (2012).","journal-title":"Am. J. Ophthalmol."},{"key":"97889_CR42","unstructured":"Database vendor (JMDC Inc. ) (2024). https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database"},{"key":"97889_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2188\/jea.JE20090066","volume":"20","author":"S Kimura","year":"2010","unstructured":"Kimura, S., Sato, T., Ikeda, S., Noda, M. & Nakayama, T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J. Epidemiol. 20, 413\u2013419 (2010).","journal-title":"J. Epidemiol."},{"key":"97889_CR44","doi-asserted-by":"publisher","first-page":"e0237617","DOI":"10.1371\/journal.pone.0237617","volume":"15","author":"N Ooba","year":"2020","unstructured":"Ooba, N. et al. Comparison between high and low potency Statins in the incidence of open-angle glaucoma: A retrospective cohort study in Japanese working-age population. PLoS One. 15, e0237617 (2020).","journal-title":"PLoS One"},{"key":"97889_CR45","unstructured":"Ministry of Health. Labour and welfare, Japan. Public health insurance for all Japanese citizens aged 75 or older (late-stage medical care system for the elderly (2024). https:\/\/www.mhlw.go.jp\/bunya\/iryouhoken\/iryouhoken01\/dl\/01_eng.pdf"},{"key":"97889_CR46","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","volume":"158","author":"WA Ray","year":"2003","unstructured":"Ray, W. A. Evaluating medication effects outside of clinical trials: new-user designs. Am. J. Epidemiol. 158, 915\u2013920 (2003).","journal-title":"Am. J. Epidemiol."},{"key":"97889_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund, J. L., Richardson, D. B. & St\u00fcrmer, T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr. Epidemiol. Rep. 2, 221\u2013228 (2015).","journal-title":"Curr. Epidemiol. Rep."},{"key":"97889_CR48","unstructured":"Anatomical Therapeutic Chemical (ATC). classification system (2024). https:\/\/atcddd.fhi.no\/atc_ddd_index\/"},{"key":"97889_CR49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2147\/CLEP.S358277","volume":"14","author":"K Kubota","year":"2022","unstructured":"Kubota, K. & Ooba, N. Effectiveness and safety of reduced and standard daily doses of direct oral anticoagulants in patients with nonvalvular atrial fibrillation: a cohort study using National database representing the Japanese population. Clin. Epidemiol. 14, 623\u2013639 (2022).","journal-title":"Clin. Epidemiol."},{"key":"97889_CR50","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/CLEP.S20247","volume":"3","author":"S Christensen","year":"2011","unstructured":"Christensen, S., Johansen, M. B., Christiansen, C. F., Jensen, R. & Lemeshow, S. Comparison of Charlson comorbidity index with SAPS and APACHE scores for prediction of mortality following intensive care. Clin. Epidemiol. 3, 203\u2013211 (2011).","journal-title":"Clin. Epidemiol."},{"key":"97889_CR51","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/bmj.330.7497.960","volume":"330","author":"M Mamdani","year":"2005","unstructured":"Mamdani, M. et al. Reader\u2019s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 330, 960\u2013962 (2005).","journal-title":"BMJ"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97889-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97889-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97889-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T15:02:29Z","timestamp":1745074949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97889-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97889"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97889-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13594"}}